HRP20180049T1 - Derivati diazakarbazola kao tau-pet ligandi - Google Patents
Derivati diazakarbazola kao tau-pet ligandi Download PDFInfo
- Publication number
- HRP20180049T1 HRP20180049T1 HRP20180049TT HRP20180049T HRP20180049T1 HR P20180049 T1 HRP20180049 T1 HR P20180049T1 HR P20180049T T HRP20180049T T HR P20180049TT HR P20180049 T HRP20180049 T HR P20180049T HR P20180049 T1 HRP20180049 T1 HR P20180049T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- image
- tau
- compounds
- Prior art date
Links
- BZHCVCNZIJZMRN-UHFFFAOYSA-N 9h-pyridazino[3,4-b]indole Chemical class N1=CC=C2C3=CC=CC=C3NC2=N1 BZHCVCNZIJZMRN-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229910052722 tritium Chemical group 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims 2
- FDMOHTOITMTGNG-UHFFFAOYSA-N 11-(6-fluoropyridin-3-yl)-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene Chemical compound Fc1ccc(cn1)-c1ccc2c(n1)[nH]c1ccncc21 FDMOHTOITMTGNG-UHFFFAOYSA-N 0.000 claims 1
- FJSKXQVRKZTKSI-UHFFFAOYSA-N 2,3-dimethylfuran Chemical compound CC=1C=COC=1C FJSKXQVRKZTKSI-UHFFFAOYSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 235000010338 boric acid Nutrition 0.000 claims 1
- 125000005619 boric acid group Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003682 fluorination reaction Methods 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 229910052741 iridium Inorganic materials 0.000 claims 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims 1
- 210000005171 mammalian brain Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000003270 potassium fluoride Nutrition 0.000 claims 1
- 239000011698 potassium fluoride Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- 239000010948 rhodium Substances 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (8)
1. Spoj, naznačen time, da ima formulu:
[image]
u kojoj
R je vodik ili tricij;
F je fluor ili 18fluor;
ili njegova farmaceutski prihvatljiva kiselinska adicijska sol.
2. Spojevi formule I prema zahtjevu 1, naznačeni time, da su ti spojevi sljedeći:
2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirol,
3H-2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirol,
i [18F]-2-(6-fluoro-piridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirol.
3. Postupak proizvodnje spoja formule I u skaldu s jednim od zahtjeva 1 ili 2, naznačen time, da postupak obuhvaća sljedeće korake:
a) spajanje spoja formule 2 (X = Cl, Br)
[image]
s prikladnim bornim kiselinama ili esterima borne kiseline formule 3
[image]
pri čemu je R’ vodik ili niži alkil, kako bi se stvorili spojevi formule I
[image]
pri čemu je R vodik,
te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spoj formule I, pri čemu je R tricij;
ili
b) spajanje spoja formule 4
[image]
s prikladnim reagensima za fluorinaciju odabranim od kalijeva fluorida ili
tetrabutilamonijevog fluorida,
kako bi se stvorili spojevi formule I
[image]
pri čemu supstituent R je vodik,
te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spojeve formule I pri čemu je R tricij,
c) reakcija spoja formule I
[image]
u kojoj je R vodik,
s tricijevim plinom u prisutnosti katalizatora iridija, rutenija, rodija ili paladija, u prikladnom otapalu koje je odabrano između diklorometana, klorobenzena, dimetilfurana, dimetilsulfoksida ili njihovih smjesa, kako bi se stvorio spoj formule I
[image]
gdje je R tricij, te ako je poželjno, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli, ili
d) otapanje spoja formule 10
[image]
u dimetilsulfoksidu i podvrgavanje sonikaciji prije kraja bombardiranja s vodenim [18]fluoridnim ionom za spoj formule
[image]
te ako je poželjno, pretvaranje dobivenih spojeva u farmaceutski prihvatljive kiselinske adicijske soli.
4. Spoj formule I u skladu s bilo kojim od zahtjeva 1 ili 2, naznačen time, da se upotrebljava u vezivanju i snimanju tau-agregata, beta-amiloidnih agregata ili alfa-sinukleinskih agregata.
5. Spoj formule I u skladu s bilo kojim od zahtjeva 1 ili 2, naznačen time, da se upotrebljava u vezivanju i snimanju tau-agregata kod pacijenata s Alzheimerom.
6. Spoj formule I u skladu s bilo kojim od zahtjeva 1 ili 2, naznačen time, da se upotrebljava u slikovnoj dijagnostici tau-agregata u mozgu sisavca.
7. Farmaceutski pripravak, naznačen time, da obuhvaća spoj formule I u skladu s bilo kojim od zahtjeva 1 ili 2, zajedno s farmaceutski prihvatljivim nosačem.
8. Postupak snimanja naslaga tau-agregata, naznačen time, da obuhvaća sljedeće korake:
- uvođenje u sisavca takve količine pripravka u skladu sa zahtjevom 8, koja se može detektirati;
- ostavljanje dovoljnog vremena za omogućavanje sjedinjavanja spoja formule I s naslagama tau-agregata; i
- detektiranje spoja sjedinjenog s jednom ili više naslaga tau-agregata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13187764 | 2013-10-08 | ||
| PCT/EP2014/071283 WO2015052105A1 (en) | 2013-10-08 | 2014-10-06 | Diazacarbazole derivatives as tau-pet-ligands |
| EP14781169.9A EP3055308B1 (en) | 2013-10-08 | 2014-10-06 | Diazacarbazole derivatives as tau-pet-ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180049T1 true HRP20180049T1 (hr) | 2018-02-09 |
Family
ID=49301396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180049TT HRP20180049T1 (hr) | 2013-10-08 | 2018-01-10 | Derivati diazakarbazola kao tau-pet ligandi |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10004817B2 (hr) |
| EP (1) | EP3055308B1 (hr) |
| JP (1) | JP6194416B2 (hr) |
| KR (1) | KR101770531B1 (hr) |
| CN (1) | CN105358558B (hr) |
| AR (1) | AR097931A1 (hr) |
| AU (1) | AU2014333996B2 (hr) |
| CA (1) | CA2917191C (hr) |
| CL (1) | CL2016000728A1 (hr) |
| CR (1) | CR20150663A (hr) |
| DK (1) | DK3055308T3 (hr) |
| EA (1) | EA028483B1 (hr) |
| ES (1) | ES2657121T3 (hr) |
| HK (1) | HK1215574A1 (hr) |
| HR (1) | HRP20180049T1 (hr) |
| HU (1) | HUE035413T2 (hr) |
| IL (1) | IL243249A0 (hr) |
| LT (1) | LT3055308T (hr) |
| MA (1) | MA38935B1 (hr) |
| MX (1) | MX2016002234A (hr) |
| MY (1) | MY190196A (hr) |
| NO (1) | NO3055308T3 (hr) |
| PE (1) | PE20160159A1 (hr) |
| PH (1) | PH12016500249A1 (hr) |
| PL (1) | PL3055308T3 (hr) |
| PT (1) | PT3055308T (hr) |
| RS (1) | RS56777B1 (hr) |
| SG (1) | SG11201602786UA (hr) |
| SI (1) | SI3055308T1 (hr) |
| TW (1) | TWI513698B (hr) |
| UA (1) | UA116164C2 (hr) |
| WO (1) | WO2015052105A1 (hr) |
| ZA (1) | ZA201509013B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247558B2 (en) | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| AR097931A1 (es) | 2013-10-08 | 2016-04-20 | Hoffmann La Roche | Derivados de diazacarbazol como ligandos de tau para pet |
| PL3143011T3 (pl) * | 2014-05-13 | 2021-07-19 | F. Hoffmann-La Roche Ag | Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące |
| MX2017009505A (es) * | 2015-02-02 | 2017-11-02 | Ucb Biopharma Sprl | Derivados de 9h-pirrolo-dipiridina. |
| EP3118202A1 (en) | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dihydropyridopyrrole derivatives as tau-pet-ligands |
| EP3322707A1 (en) | 2015-07-15 | 2018-05-23 | AC Immune SA | Novel imaging compounds |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| CN109475648B (zh) * | 2016-07-22 | 2023-03-14 | Ac免疫有限公司 | 用于成像tau蛋白聚集体的化合物 |
| WO2018024642A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| WO2018024643A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| CA3035624A1 (en) | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| WO2019145292A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| JP7260552B2 (ja) * | 2018-01-24 | 2023-04-18 | エーシー・イミューン・エス・アー | Ｐｅｔ画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用 |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| US20210038747A1 (en) | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Novel method of preparing an imaging compound |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247558B2 (en) * | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| US8932557B2 (en) * | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| KR20110015699A (ko) | 2008-06-11 | 2011-02-16 | 제넨테크, 인크. | 디아자카르바졸 및 사용 방법 |
| CA2731738A1 (en) | 2008-07-24 | 2010-01-28 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying ad pathology |
| US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2010111303A2 (en) | 2009-03-23 | 2010-09-30 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological disorders |
| US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| US20150368244A1 (en) * | 2011-01-31 | 2015-12-24 | Genentech, Inc. | Diazacarbazoles and methods of use |
| AR097931A1 (es) * | 2013-10-08 | 2016-04-20 | Hoffmann La Roche | Derivados de diazacarbazol como ligandos de tau para pet |
-
2014
- 2014-10-06 AR ARP140103712A patent/AR097931A1/es active IP Right Grant
- 2014-10-06 MX MX2016002234A patent/MX2016002234A/es active IP Right Grant
- 2014-10-06 PT PT147811699T patent/PT3055308T/pt unknown
- 2014-10-06 CN CN201480037389.5A patent/CN105358558B/zh active Active
- 2014-10-06 MY MYPI2016000604A patent/MY190196A/en unknown
- 2014-10-06 PE PE2015002706A patent/PE20160159A1/es active IP Right Grant
- 2014-10-06 TW TW103134795A patent/TWI513698B/zh active
- 2014-10-06 EA EA201690515A patent/EA028483B1/ru not_active IP Right Cessation
- 2014-10-06 HU HUE14781169A patent/HUE035413T2/en unknown
- 2014-10-06 JP JP2016515518A patent/JP6194416B2/ja active Active
- 2014-10-06 WO PCT/EP2014/071283 patent/WO2015052105A1/en active Application Filing
- 2014-10-06 LT LTEP14781169.9T patent/LT3055308T/lt unknown
- 2014-10-06 PL PL14781169T patent/PL3055308T3/pl unknown
- 2014-10-06 ES ES14781169.9T patent/ES2657121T3/es active Active
- 2014-10-06 SG SG11201602786UA patent/SG11201602786UA/en unknown
- 2014-10-06 AU AU2014333996A patent/AU2014333996B2/en active Active
- 2014-10-06 DK DK14781169.9T patent/DK3055308T3/en active
- 2014-10-06 RS RS20180058A patent/RS56777B1/sr unknown
- 2014-10-06 UA UAA201604290A patent/UA116164C2/uk unknown
- 2014-10-06 EP EP14781169.9A patent/EP3055308B1/en active Active
- 2014-10-06 CA CA2917191A patent/CA2917191C/en active Active
- 2014-10-06 SI SI201430549T patent/SI3055308T1/en unknown
- 2014-10-06 NO NO14781169A patent/NO3055308T3/no unknown
- 2014-10-06 KR KR1020167008013A patent/KR101770531B1/ko active IP Right Grant
-
2015
- 2015-12-10 ZA ZA2015/09013A patent/ZA201509013B/en unknown
- 2015-12-15 CR CR20150663A patent/CR20150663A/es unknown
- 2015-12-21 IL IL243249A patent/IL243249A0/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500249A patent/PH12016500249A1/en unknown
- 2016-03-24 HK HK16103514.3A patent/HK1215574A1/zh unknown
- 2016-03-25 MA MA38935A patent/MA38935B1/fr unknown
- 2016-03-30 CL CL2016000728A patent/CL2016000728A1/es unknown
- 2016-04-07 US US15/093,366 patent/US10004817B2/en active Active
-
2018
- 2018-01-10 HR HRP20180049TT patent/HRP20180049T1/hr unknown
- 2018-05-15 US US15/980,080 patent/US11058781B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180049T1 (hr) | Derivati diazakarbazola kao tau-pet ligandi | |
| HRP20201984T1 (hr) | Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida | |
| HRP20201480T1 (hr) | Derivati indolinona i postupak za njihovu proizvodnju | |
| JP2014508731A5 (hr) | ||
| SG188444A1 (en) | Method for rapid preparation of suitable [18f]fluoride for nucleophilic [18f]fluorination. | |
| RU2014110400A (ru) | Способ и промежуточные соединения для получения макролактамов | |
| JP2008542286A5 (hr) | ||
| HRP20171397T4 (hr) | Postupak proizvodnje liganada amiloida beta obilježenih s f-18 | |
| HRP20171167T1 (hr) | Priprava intermedijera pirimidina koji služe za proizvodnju macitentana | |
| HRP20191882T1 (hr) | Smanjivanje veličine čestice antimuskarinskog spoja | |
| HRP20121026T1 (hr) | Postupak za dobivanje kaspofungina i njegovih intermedijera | |
| HRP20201372T1 (hr) | Radioaktivno označeni pet mglur2/3 ligandi | |
| GB2519026B (en) | Preparation of 18F-fluciclovine | |
| HRP20191632T1 (hr) | Kemijski postupak dobivanja spiroindolona i njihovih međuprodukata | |
| Liu et al. | Stereoselective Construction of Nitrile‐Substituted Cyclopropanes from 2‐Substituted Ethenesulfonyl Fluorides via Carbon‐Sulfur Bond Cleavage | |
| JP5688808B2 (ja) | 高速フルオロメチル化法及びそれを利用したｐｅｔトレーサーの製造方法 | |
| EP2463263A4 (en) | ISOTOPE-MARKED 2-ARYLPROPIONIC ACID COMPOUNDS, PROCESS FOR PRODUCING THE SAME, MOLECULAR PROBE FOR POSITRON EMISSION TOMOGRAPHY (PET), AND CYCLO-OXYGENASE IMAGING METHOD AND ANALOGY THEREFOR | |
| Bonte et al. | Investigation of the Pyridinium Ylide—Alkyne Cycloaddition as a Fluorogenic Coupling Reaction | |
| SI3083557T1 (en) | PROCESSES FOR PREPARATION OF ESTROV 3-SUBSTITUTED (INDOL-1-IL) -OXETIC ACID | |
| CA2929779A1 (en) | Process for fluorinating compounds | |
| HRP20110824T1 (hr) | Predlijekovi nalmefena | |
| Rami-Mark et al. | Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter:[11C] IPCIT and [18F] FE@ IPCIT | |
| WO2014014067A1 (ja) | sp3炭素のメチル化法 | |
| DE102017125533A1 (de) | 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung | |
| WO2012105814A3 (ko) | 개선된 플루오르-18 표지를 위한 트리아자노난 유도체 또는 이의 약학적으로 허용가능한 염 |